The second dose group clinical trial of IMM01 project was successfully completed
On March 26, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM01, the first Fc fusion protein drug targeting human CD47, has successfully completed the second dose group clinical trial in the Hematology Hospital of Chinese Academy of Medical Sciences, and will be enrolled in the third dose group in the near future.
The second dose group was a patient with relapsed and refractory follicular lymphoma. During DLT observation, routine examination found that the tumor shrank, the physical condition was significantly improved, and self-esteem was good. The patient did not want to be out of the group and chose to continue medication. "We are very glad to learn that our IMM01 project can work at such a low dose and benefit patient. This may be closely related to our molecular design, because IMM01 does not bind to red blood cells at all, thus avoiding the " antigenic sink " caused by this. At the same time, due to the elimination of glycosylation, PK is improved and the drug bioavailability is high.". Dr. Tian Wenzhi, founder of ImmuneOnco, is full of confidence in the clinical trial of IMM01, "we will work closely with clinical experts and subjects to accelerate the clinical trial research of IMM01 and speed up the marketing of IMM01, so as to let relapsed and refractory cancer patients benefit as soon as possible.".